BIO CEO Advisory Committee

  • Recommend
  • Tweet
  • Print
  • Email


Tom M. Brakel, MD
Senior Portfolio Manager & Senior Investment Analyst, Federated Kaufmann Funds

Tom M. Brakel has been with Federated Kaufmann Funds since 2003 and has been a Portfolio Manager since 2009. Mr. Brakel focuses on security selection with particular emphasis in the health sector. Prior to the financial industry, Mr. Brakel spent five years at Organon Pharmaceuticals. Mr. Brakel earned an M.D. from Erasmus University, The Netherlands, and an M.B.A. from Stanford University.

John Chambers
Managing Director & Head of Healthcare Investment Banking, ROTH Capital Partners

John Chambers, a Managing Director and Head of Healthcare Investment Banking group, joined ROTH Capital Partners in December 2009. Chambers was formerly the head of Merriman Curhan Ford’s Heath Care and investment banking team. Prior to joining Merriman, Chambers was co-head of investment banking at Rodman & Renshaw. He has also held senior-level health care and biotechnology banking positions at SG Cowen, Lehman Brothers, UBS and Salomon Smith Barney. Chambers has executed a significant number of banking transactions, strategic transactions and restructurings across all health care sectors.

Chambers earned his MBA from Columbia Business School and his BS in mechanical engineering from Union College.

Bernard Davitian
Vice President & Managing Director, Sanofi-Genzyme BioVentures

Bernard Davitian has extensive experience in the life sciences and biotech industry, marked by a number of closed transactions involving financings and M&A. His track record includes, among others, the successful IPO of Transgene on the NASDAQ and Euronext in 1998 ($100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a €370 million cash transaction.

Bernard joined Sanofi in 2010 as Vice President, Deputy Global Head, Corporate Licenses and was promoted to Vice President, BD Licensing and Structured Investments in 2012, a role that includes the management of SGBV. Prior to his joining Sanofi, Bernard was EVP & CFO of Fovea Pharmaceuticals, CEO of Neurotech, and EVP & CFO of Transgene. Bernard began his career in the biotech sector by serving in various capacities at Institut Mérieux (now Sanofi Pasteur), including Corporate CFO.

Michael Hay
Executive VP, BioMedTracker Product Director, Sagient Research Systems

Michael Hay, Executive Vice President, Sagient Research Systems.  Michael has been with Sagient for over eight years and has over 12 years of financial markets experience.  He manages the BioMedTracker analyst team and serves as Executive Vice President at Sagient, which was acquired by Informa in 2012.  He is also responsible for product development, corporate planning and sales and marketing.

Michael has consulted numerous top-tier pharmaceutical companies on strategic decisions as well as worked closely with top healthcare investment firms providing insight on investment and trading decisions.  Michael served on the BIO CEO advisory board in 2012.  Michael's financial markets career began at Thomson Financial in 2000.  He reached the position of Manager, Capital Markets Intelligence and was directly responsible for corporate client relationships within the Technology sector.  At Thomson he consulted senior management regarding shareholder composition, financial markets and competitive positioning.

Michael received a Bachelor of Science degree in Finance from University of Colorado, Boulder.

Annalisa Jenkins, MBBS, MRCP
Executive VP and Head of Global Research and Development, Merck KGaA

Annalisa Jenkins, MBBS, MRCP, is Executive Vice President, Head of Global Development and Medical for Merck Serono. Dr. Jenkins is also a member of the Pharmaceutical Executive Committee.

Prior to joining Merck Serono, Dr. Jenkins was Senior Vice President, Global Medical Affairs at Bristol-Myers Squibb (BMS). She started with BMS in 1997 as a Cardiovascular Medical Advisor based in the UK. In 2000, she moved to Australia to serve as Executive Medical Director for Australia and New Zealand, subsequently leading the Medical Division across Asia Pacific and Latin America.

In 2002, Dr. Jenkins moved to BMS’s major R&D site in Princeton, New Jersey, to oversee the company’s International Medical Division. After three years in this role, she was appointed Chief Medical Officer (CMO) for Europe, Middle East and Africa, subsequently taking on the position of Senior Vice President and CMO responsible for the Americas and the Development Teams.

Annalisa Jenkins began her career as a Medical Officer with the British Royal Navy, and served with the Minesweeper Squadron during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. She graduated in Medicine from St Bartholomew’s Hospital London and trained in Cardiology with the UK National Health Service.

Peter Kolchinsky, PhD
Managing Director, RA Capital Management, LLC

Peter Kolchinsky, PhD is a founding Partner and Portfolio Manager at RA Capital. Mr. Kolchinsky is active in both public and private investments across drugs, medical devices, diagnostics, and life-science tools. He authored the e-book “the Entrepreneur’s Guide to a Biotech Startup”, serves on the board of the American Fertility Association, and is a board member of several private healthcare companies. In the past, he has served on the Board of Global Science and Technology for the National Academies of Sciences. Mr. Kolchinsky received a Ph.D. in Virology from Harvard University. His doctoral work involved studies of the mechanism by which HIV infects cells. He received a Bachelors degree from Cornell University.

Arlene M. Morris
CEO, Syndax Pharmaceuticals, Inc.

Arlene Morris was named CEO of Syndax in 2012 after working as a director of the company for nine months.

Syndax Pharmaceuticals is a late-stage oncology company supported by top venture capitalists and led by industry experts developing treatments for large markets including metastatic breast and lung cancer. The company’s platform is based on employing epigenetics to overcome the problem of resistance in oncology care.

Targeted therapies represent an important class of agents used to treat both breast and lung cancers based on blocking the tumor’s addiction to growth promoting signals.

Prior to Syndax, Ms. Morris served as chief executive officer and member of the board of directors for Affymax, Inc., a biopharmaceutical company located in Palo Alto, Calif., which was spun out of GlaxoSmithKline (GSK) in 2001 to develop a pipeline of synthetic peptide-based drug candidates for the treatment of anemia in dialysis patients. During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of peginesatide (Omontys®), a strategic collaboration with Takeda and an Initial Public Offering of $90 million. She also raised private C and D rounds of $100 million.


Oleg Nodelman
Founder & Managing Director, EcoR1 Capital

Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital, a San Francisco-based, value-oriented healthcare investment fund.  EcoR1 capitalizes on opportunities in the biotechnology sector and mitigates risk through a highly engaged investment process, emphasizing the value of identifying and recruiting premier human capital in all aspects of corporate management and scientific leadership. 

Prior to EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners L.P., one of the oldest dedicated biotechnology hedge funds.  At BVF, Mr. Nodelman’s responsibilities included all aspects of the business including opportunity generation, deep diligence, portfolio management and trading.  Prior to joining BVF in 2001, Mr. Nodelman was a consultant with Mercer Management Consulting (now Oliver Wyman), a consulting firm focused on strategy, operations, risk management, organizational transformation and leadership development.  At Mercer, he worked with senior management from companies in a variety of industries to develop and implement long-term strategy and build shareholder value. 

Mr. Nodelman is on the Board of Addex Therapeutics (SIX: ADXN) and a is member of the President's Council at the Gladstone Institute. He holds a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.

David Sable, MD
Portfolio Manager, Special Situations Life Sciences Fund

David Sable, MD, directs healthcare and life science investing for the Special Situations Funds and is portfolio manager of the Special Situations Life Sciences Fund. After graduating from the Wharton School and the University of Pennsylvania School of Medicine, residency in obstetrics and gynecology at New York Hospital - Cornell Medical Center, fellowship at Brigham and Women's Hospital, and clinical practice at Harvard Medical School and MIT, he co-founded the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey. He subsequently founded Assisted Reproductive Medical Technologies, which was acquired in 2000.

After leaving clinical medicine at age 43, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations group. Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences, has lectured on healthcare investing, policy, and biotechnology business development at the Wharton School, NYU, Rockefeller University and Rutgers; has delivered keynote addresses to the American Fertility Society, the Texas Fertility Society and the Mexican Fertility Society; and appeared on the CBS Morning News, ABC World News Tonight, NY1 News and PBS’ Nova. In addition to his academic publications, he has written for the Newark Star-Ledger, Yoga Journal, Genetic Engineering and Biotechnology News, Xconomy, Nature Biotechnology, and the Columbia Spectator.

Hans GCP Schikan, PharmD
Chief Executive Officer, Prosensa

Hans Schikan is CEO of Prosensa, an innovative Dutch biopharmaceutical company focusing on the discovery, development and commercialization of novel treatments for rare diseases like Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease, using its RNA modulation platform. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles, including as Vice President for Global Marketing and Strategic Development of Genzyme’s portfolio of products for rare genetic diseases. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Next to his role at Prosensa, Hans is currently Executive Board Member of the Dutch Top Institute Pharma, Non-executive Director of Sobi (Swedish Orphan Biovitrum) and Member of the Core Team of the Dutch Top Sector Life Sciences & Health. He is also past Chairman of Nefarma, the Dutch Association of Research Based Pharmaceutical Industry. He has a PharmD from Utrecht University.

Nathan Tinker, PhD
Executive Director, New York Biotechnology Association

Nathan Tinker is Executive Director of the New York Biotechnology Association (NYBA), the statewide trade association representing New York’s bioscience community.   As Executive Director, Dr. Tinker serves as a spokesman and advocate for the state’s industry. NYBA supports the development and growth of New York State's biotechnology industry, and serves its members and the biotechnology community by providing a network for information exchange, shared services, and collective action.

Dr. Tinker comes to NYBA with a deep knowledge and awareness of the industry and its unique strengths in New York. He has more than 15 years of experience in working with both global and emerging technology companies.  Immediately prior to joining NYBA, Dr. Tinker served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as a Director of the Nanotechnology and Biotechnology Practice at Antenna Group, a boutique communications firm.  Before that, Nathan was Co-Founder and Executive Vice President of the NanoBusiness Alliance, the national trade association for nanotechnology.  Dr. Tinker began his career in market research and communications, serving such clients as Apple, eSpeed, Sprint, Cantor Fitzgerald, DaimlerChrysler, Yahoo!, CSX, and many others.

Dr. Tinker lends his talent and knowledge to industry on corporate boards, including the advisory boards of Physicians Interactive Holdings, Viral Genetics, Versilant Technologies and Namar Consulting, as well as with non-profit groups, including Nanotechnology Commercialization Association and the Kingsborough College Bioscience Advisory Committee.